Genmab A/S (GMAB) News
Filter GMAB News Items
GMAB News Results
|Loading, please wait...|
GMAB News Highlights
- For GMAB, its 30 day story count is now at 23.
- Over the past 28 days, GMAB's stories per day has been in a clear downtrend, falling by about 0.36 per 3 days.
- AG, PEAK and PLX are the most mentioned tickers in articles about GMAB.
Latest GMAB News From Around the Web
Below are the latest news stories about Genmab A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
Analysts predict that Genmab A/S (NASDAQ:GMAB) will post earnings of $0.11 per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Genmab A/Ss earnings, with estimates ranging from $0.10 to $0.13. Genmab A/S posted earnings of $0.13 per share during the same quarter last year, which would suggest 
Bank of Montreal Can boosted its stake in Genmab A/S (NASDAQ:GMAB) by 250.0% in the 2nd quarter, Holdings Channel reports. The firm owned 36,313 shares of the companys stock after acquiring an additional 25,938 shares during the quarter. Bank of Montreal Cans holdings in Genmab A/S were worth $1,484,000 at the end of the most 
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
Media Release Copenhagen, Denmark, October 15, 2021
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Company Announcement COPENHAGEN, Denmark; October 7, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 18,689 restricted stock units and 21,537 warrants to employees of the company and three of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancers 36th Annual Meeting (SITC 2021)
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
COPENHAGEN, Denmark, October 01, 2021--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company’s solid tumor product pipeline will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), being held in Washington, DC, and virtually, November 10-14. The presentations will include a mini-oral session featuring the results of the first-in-human (FIH) phase 1/2 trial evaluating th
(PLX AI) - Genmab may see Tivdak peak sales of $1.11 billion, Nordea analysts forecast, raising their price target on the stock. Price target raised to DKK 3,188 from DKK 3,058, with recommendatio
Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co.